🎥 Our most recent youtube video features breaking data from IBC East and conversations with leading breast cancer oncologists 🎥. Check it out here: #bcsm | @gotoPER

Pembrolizumab plus axitinib yielded a median OS of 47.2 months vs 40.8 months with sunitinib in patients with advanced renal cell carcinoma. #kcsm #oncology | @brian_rini.

"However, we must always be careful when you use MRD as an end point because patients with high-risk disease could relapse quickly. " said Shebli Atrash, MD. #oncology #mmsm | @AtrashShebli @LevineCancer.

The FDA has granted accelerated approval to dordaviprone for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. #btsm #oncology #ApprovalAlert |

Approximately half of patients with ovarian cancer who achieve clinical remission following first-line therapy harbor evaluable minimal residual disease, which may inform the development of novel targeted therapies and clinical trials. #gyncsm #oncology.

The FDA has accepted an sBLA for and granted priority review to liso-cel in the treatment of patients with relapsed or refractory marginal zone lymphoma who received at least 2 prior lines of systemic therapy. #lymsm #oncology.

New on Between the Lines!.Episode 2: “CAR T Monitoring Strategies: Balancing Patient Safety With Quality of Life Considerations”.Featuring:.• Dr. Mazyar Shadman, MD, MPH of @fredhutch.• Dr. Sayeef Mirza, MD, MPH, FACP of @MoffittNews.Watch now to get the latest updates on

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD. #CART #oncology | @KUMedCenter @Abdallah81MD

Standard treatment options for patients with locally advanced or metastatic EGFR-mutant non–small cell lung cancer have led to a “complicated conversation,” according to Jacob Sands, MD. #NSCLC #lcsm #oncology | @DanaFarber @sands_jacob.

For the first time since the 2018 Chicago Consensus, new clinical guidelines outlining a unified approach to treating peritoneal surface malignancies have been published. #oncology | @kturaga @YaleCancer.

"As a course director for the ICE-T symposium, the whole ICE-T concept was to bring our academic knowledge and our academic leaders [together] with community leaders to try and get increased access out in the community," said Nausheen Ahmed, MD. #CART.

Data from the phase 3 DeLLphi-304 trial shared at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC. #SCLC #lcsm #oncology | @wakeforestmed.

The developer announced that the CRL was related to observations from an FDA general site inspection at Catalent Indiana LLC. #lymsm #oncology

Trispecifics are generating major buzz in relapsed/refractory Multiple Myeloma—and for good reason. In this Around the Practice episode, experts, : @AjaiChari, @AjayNookaMD, @MMBaljevicMD, @GKaurMD, and @anupamakumar05, discuss early data, safety advantages, and why this

High doses of aumolertinib led to a median PFS of 20.5 months, which included a 12-month rate of 62.1% and a 24-month rate of 40.8%, in patients with untreated EGFR-variant NSCLC and brain metastases. #NSCLC #lcsm #oncology.

INKmune was well tolerated across 3 escalating dose levels: 1 x 108, 3 x 108, and 5 x 108 cells per infusion, and it exhibited a favorable safety profile in patients with metastatic castration-resistant prostate-cancer. #pcsm #oncology.

"If you switch away from VEGF TKIs to belzutifan, what you’ll find is that the toxicity profile—the chronic fatigue and diarrhea associated with VEGF TKIs—can be switched off by [choosing belzutifan]," said Thomas Powles, MBBS, MCRP, MD. #kcsm #KCRS2025.

One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials. #kcsm | @MSKCancerCenter.

Although treatment for SCLC has seen minimal changes over the last 30 years, DLL3 holds promise as an actionable biomarker for novel cellular therapy agents like tarlatamab. #SCLC #lcsm | @DCarrizosaMD.

The addition of talazoparib to enzalutamide exhibited enhanced OS vs enzalutamide plus placebo in patients with metastatic CRPC receiving ongoing androgen deprivation therapy, and naive to previous life-prolonging systemic therapy. #pcsm #oncology.

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent. #oncology